Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaMg versus sevelamer and calcium carbonate for vascular stiffness in chronic hemodialysis with hyperphosphatemia
TCTR20260908003Phase 3Recruiting
- Sponsor
- Thai Red Cross Society
- Start
- Apr 2026
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of calcium acetate + magnesium carbonate, sevelamer carbonate, calcium carbonate in hyperphosphatemia, end-stage kidney disease (ESKD), sponsored by Thai Red Cross Society. Started Apr 2026; status: recruiting.
02
Drugs
calcium acetate + magnesium carbonatesevelamer carbonatecalcium carbonate
03
Conditions
hyperphosphatemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on TCTR20260908003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260908003.